Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Shenderov, E; Marzo, AM De; Lotan, TL; Wang, H; Chan, S; Lim, Soon Tjin; Ji, H; Allaf, ME; Chapman, C; Pa, Moore; Chen, F; Sorg, K; White, A.; Church, SE; Hudson, B; Pa, Fields; Hu, S; Denmeade, SR; Palovich, CP; Ross, AE; Drake, CG; Pardoll, DM; Antonarakis, ES

doi:10.21417/es2023nm

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical work targeting B7-H3 has demonstrated promising antitumor activity [125,127,[130][131][132][133][134] . Other studies have demonstrated that defects in tumor suppressor genes, namely TP53 and PTEN, have been associated with increased B7-H3 levels.…”

Section: B7-h3 (Cd276)mentioning

confidence: 99%

“…Other preclinical studies have observed that monoclonal antibodies, such as enoblituzumab, have been combined with PD-L1 inhibitors with dramatic success and have spurred further combination treatment approaches with ipilimumab, a CTLA-4 inhibitor, with clinical studies currently underway in patients with melanoma and non-small cell lung cancer (NCT02381314) [132][133] . Further drug development targeting B7-H3 is rapidly underway, encompassing multiple classes of therapy including ADCs (DS-7300/MGC018), checkpoint inhibitors, tri-specific killer engager agents (TriKE), CAR natural killer cell agents (CAR-NK), and CAR-T therapies [126,127,132,133] . Topline results from early-phase studies of these therapies are demonstrating a favorable safety profile [127] .…”

Section: B7-h3 (Cd276)mentioning

confidence: 99%

See 1 more Smart Citation

Tumor-associated antigen targets for novel immune-based strategies in prostate cancer

Bhasin,

Mille,

Eturi

et al. 2024

J Transl Genet Genom

View full text Add to dashboard Cite

Prostate cancer remains the most common malignancy among men in the United States. Advancements in androgen receptor signaling blockade have led to landmark approvals for its use in patients with locally advanced and metastatic disease. However, additional novel therapeutic strategies for both hormone-sensitive and castration-resistant diseases remain ongoing areas of study. Thus, we turn to the growth of immuno-oncology, which has led to improved treatment outcomes for a variety of hematologic and solid tumor malignancies. Prostate cancers have shown only modest results with immune checkpoint inhibition in published trials, and innovative strategies are now looking into enhancing cytotoxic T-cell activity against cancer cells. This review provides a thorough evaluation of tumor-associated antigens that are integrated into novel chimeric antigen receptor T-cell and bispecific T-cell engager therapies. Our review will evaluate the most recent advancements in immunotherapies, while also illustrating major obstacles and underlying limiting factors.

show abstract